Arcturus Therapeutics Holdings Inc. (ARCT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Arcturus Therapeutics (ARCT) Q1 2026: Cash Runway Extends Beyond 2 Years as Rare Disease Pipeline Advances
  May 08, 2026
• Arcturus Therapeutics (ARCT) Q4 2025: Cash Runway Extended to 2028 as Rare Disease Pipeline Advances
  March 04, 2026
• Arcturus Therapeutics (ARCT) Q3 2025: OpEx Down 36% as Pipeline Refocuses on CF and OTC Milestones
  November 11, 2025
• Arcturus Therapeutics (ARCT) Q3 2024: $25M Milestone Secured as CoStave Commercialization Scales in Japan
  November 07, 2024
• Arcturus Therapeutics (ARCT) Q2 2024: Revenue Jumps 376% on CSL Milestones, Japan Vaccine Launch in Focus
  August 05, 2024
• Arcturus Therapeutics (ARCT) Q1 2024: $17M R&D Surge Signals Pipeline Acceleration Ahead of CoStave Launch
  May 08, 2024
• Arcturus Therapeutics (ARCT) Q4 2023: $396M Milestone Payments Extend Runway, Vaccine Platform Validated
  March 07, 2024
• Arcturus Therapeutics (ARCT) Q3 2023: $365M CSL Milestones Extend Cash Runway to 2026 as Japan Approval Nears
  November 14, 2023

Browse all companies